NLE Gastrointestinal Nursing — Lower GI & Bowel DisordersStudy Notes

The lower gastrointestinal tract begins at the pyloric sphincter and extends to the anus, comprising the small intestine (duodenum, jejunum, ileum), colon (cecum, ascending, transverse, descending, sigmoid), rectum, and anal canal. Functionally, the small intestine is the primary site of nutrient absorption through its extensive mucosal surface area enhanced by villi and microvilli, whereas the colon absorbs water and electrolytes, forming stool for elimination. In the Philippine healthcare context, nurses working in primary care facilities must recognize that lower GI disorders vary significantly by socioeconomic factors—high-fiber intake in rural populations may reduce diverticular disease risk, while limited access to antibiotics in remote areas affects management of infectious diarrhea. The enteric nervous system, sometimes called the 'second brain,' regulates motility and secretion; dysfunction of this system underlies conditions like irritable bowel syndrome (IBS). Pathophysiologically, lower GI disorders arise from structural abnormalities (diverticula, tumors, strictures), inflammatory/infectious processes (IBD, infectious gastroenteritis), functional disturbances (IBS, paralytic ileus), or obstructive lesions (adhesions, hernias, intussusception). Recognizing the pathophysiologic mechanism guides nursing interventions within the nursing care model (NCM) framework—for example, in mechanical obstruction, nurses prioritize decompression via nasogastric tube; in IBD, nutrition support and infection monitoring are paramount. Nurses applying NANDA-I diagnosis must identify whether symptoms reflect nutritional imbalance, fluid and electrolyte disturbance, altered body image (ostomy), or risk for infection—each requiring distinct priority interventions aligned with Maslow's hierarchy.

Inflammatory bowel disease (IBD) comprises two chronic, relapsing-remitting disorders of unknown etiology characterized by intestinal inflammation: Crohn's disease and ulcerative colitis (UC). These diseases are NOT variants of the same condition but distinct entities with fundamentally different anatomical locations, pathologic patterns, and clinical sequelae. The NLE frequently presents exam items testing this distinction, making it a critical high-yield topic.

CROHN'S DISEASE (Regional Ileitis):
Crohn's disease is a transmural (full-thickness) inflammation affecting any segment of the GI tract from the mouth to the anus, although the terminal ileum and proximal colon are most commonly involved (60% of cases). Pathologically, Crohn's presents as 'skip lesions'—discontinuous areas of inflammation separated by normal mucosa, reflecting the patchy, transmural nature of inflammation. This transmural involvement results in deep ulceration and fissuring, often leading to fistula formation (communication between bowel and skin, bladder, or vagina) and strictures (narrowing from fibrosis). Classic findings include cobblestone appearance of the mucosa (due to deep ulceration around islands of normal tissue), creeping fat (proliferation of fat surrounding the bowel—'fat wrapping'), and mesenteric thickening visible on imaging.

Clinically, Crohn's patients present with cramping abdominal pain (often periumbilical or RLQ), non-bloody or only mildly bloody diarrhea (4–6 stools/day typically), weight loss, and fatigue. Because Crohn's affects the small intestine, malabsorption is a hallmark complication—deficiencies in fat-soluble vitamins (A, D, E, K), vitamin B12, folate, iron, and calcium lead to anemia, bone disease, and growth retardation in children. Perianal disease (fistulas, skin tags, abscesses) is characteristic and often the first manifestation in 30% of Crohn's patients. Extraintestinal manifestations include arthralgia/arthritis (HLA-B27 associated), erythema nodosum, pyoderma gangrenosum, uveitis, and primary sclerosing cholangitis (PSC).

Surgery is NOT curative in Crohn's because inflammation can recur in previously normal bowel proximal or distal to resected segments; however, surgery is performed for complications (fistula drainage, abscess drainage, stricture dilation) or severe disease refractory to medical management. Patients require surgery at some point in their illness (>70% lifetime).

ULCERATIVE COLITIS (UC):
Ulcerative colitis is characterized by mucosal and submucosal inflammation limited to the colon and rectum only—never extends above the ileocecal valve or into the small intestine. Unlike Crohn's patchy distribution, UC inflammation is continuous, always beginning at the rectum and extending proximally in a uniform pattern (proctitis, proctosigmoiditis, left-sided colitis, or pancolitis if the entire colon is involved). Pathologically, inflammation is limited to the mucosa and submucosa; it does NOT penetrate the muscularis propria, so transmural complications (fistulas, strictures) are rare.

Clinically, UC presents with frequent, urgent, bloody, mucoid diarrhea (10–20 stools/day during flares), left lower quadrant cramping pain, and tenesmus (sensation of incomplete evacuation). Unlike Crohn's, weight loss and malabsorption are less prominent because the small intestine is spared; however, bloody diarrhea leads to iron-deficiency anemia. Extraintestinal manifestations parallel Crohn's (arthritis, skin lesions, uveitis, PSC) but are generally less common and less severe.

A critical complication specific to UC is toxic megacolon—massive dilation of the colon (>6 cm diameter on X-ray) resulting from severe inflammation and loss of muscular tone. Toxic megacolon presents as acute abdominal distension, fever, tachycardia, leukocytosis, and electrolyte derangement and is a surgical emergency because perforation risk is imminent. Nurses must recognize warning signs: sudden worsening of diarrhea, severe abdominal pain and distension, fever >38.5°C, and clinical deterioration despite medical management.

Unlike Crohn's disease, total proctocolectomy (removal of the entire colon and rectum) is CURATIVE in UC because inflammation is limited to the colon; there is no residual diseased bowel. Patients with UC or Crohn's have increased colorectal cancer risk (cumulative risk ~5–10% after 20 years of disease), necessitating surveillance colonoscopy (according to guidelines, typically every 1–2 years after 8 years of disease).

NURSING PRIORITIES IN IBD (Using NANDA-I & Maslow's Hierarchy):
According to Maslow's hierarchy, physiologic needs (fluid, electrolyte, and nutritional balance) take priority. Common nursing diagnoses include:

• Diarrhea related to inflammatory process (Maslow: physiologic) → Monitor frequency, consistency, and presence of blood; assess hydration status (skin turgor, mucous membranes, orthostatic vitals); encourage oral rehydration solution during mild diarrhea; coordinate IV fluids during severe flares
• Imbalanced Nutrition: Less Than Body Requirements related to malabsorption (Crohn's) or diarrhea → Collaborate with dietitian; implement low-residue, high-protein, high-calorie diet during flares; assess for specific malabsorption (B12 deficiency → pernicious anemia; folate deficiency → megaloblastic anemia); monitor weight and albumin/prealbumin; coordinate TPN for severe malnutrition or bowel rest
• Risk for Deficient Fluid Volume and Electrolyte Imbalance → Monitor I&O meticulously; assess for hypokalemia (diarrhea causes potassium loss → cardiac dysrhythmias, muscle weakness); monitor electrolytes (Na, K, Mg, Ca); coordinate IV replacement as prescribed; educate on signs of dehydration
• Acute Pain related to inflammation and cramping (Maslow: physiologic) → Assess pain location, timing, and relationship to bowel movements; position patient semi-Fowler's for comfort; apply warm (not hot) compress to abdomen if ordered; administer antispasmodics or analgesics as prescribed; coordinate dietary modifications to reduce pain triggers
• Risk for Infection related to bowel perforation or fistula → Assess abdomen for signs of peritonitis (rigid, board-like abdomen; severe pain; fever); report sudden improvement in pain followed by worsening rigidity (suggests rupture); monitor fever and WBC; coordinate urgent surgical evaluation if peritonitis suspected
• Disturbed Body Image (if ostomy required) or Risk for Social Isolation related to chronic diarrhea (Maslow: safety, belonging) → Support patient emotionally; provide accurate information about disease; connect to IBD support groups (available through Philippine IBD awareness organizations); encourage verbalization of concerns about sexual function, fertility (medication teratogenicity), and social stigma

During ACUTE FLARES, the nursing care model emphasizes:

1. Bowel Rest: NPO or clear liquids; advance diet gradually as inflammation settles
2. Decompression: NGT placement if ileus or obstruction suspected
3. Hydration & Electrolyte Correction: IV fluids (D5NSS or NSS with electrolyte additives), targeting urine output 200–300 mL/hour, normal serum electrolytes
4. Nutrition Support: Consider TPN for severe malnutrition, severe flares, or when NPO status prolonged >1 week
5. Monitoring for Complications: Daily abdominal assessment, fever monitoring, serial CBCs and chemistry panels, stool frequency/character/blood content

During REMISSION or MAINTENANCE, nursing priorities shift to education and symptom prevention:

1. Dietary Education: Teach that individual tolerance varies; common triggers include high-fiber, fatty, spicy, or cold foods; dairy if lactose-intolerant; caffeine and alcohol; encourage keeping a food diary
2. Medication Adherence: Reinforce that remission is maintained only with ongoing pharmacotherapy; never stop medications without MD approval
3. Stress Management & Sleep: Teach relaxation techniques, regular exercise, adequate sleep (stress exacerbates flares)
4. Regular Monitoring: Coordinate periodic colonoscopy for surveillance (every 1–2 years after 8 years disease duration) per gastroenterology recommendations
5. Psychosocial Support: Address depression/anxiety (common in chronic disease); refer to mental health services or IBD support groups

Pharmacologic therapy in IBD is tailored by disease severity, type (Crohn's vs. UC), and distribution, progressing from first-line aminosalicylates through corticosteroids, immunomodulators, and biologic agents as disease escalates or becomes steroid-dependent.

AMINOSALICYLATES (5-ASA AGENTS):
Aminosalicylates are the first-line agents for mild-to-moderate UC and mild Crohn's disease. These drugs act topically on inflamed mucosa to reduce inflammation; the exact mechanism is incompletely understood but involves decreased prostaglandin and leukotriene synthesis, reduced reactive oxygen species, and immunomodulation.

Sulfasalazine: Consists of 5-ASA linked to sulfapyridine via an azo bond. Historically the first 5-ASA agent, sulfasalazine is split by colonic bacteria into its active (5-ASA) and inactive (sulfapyridine) components. Typical dose: 2–4 g/day in divided doses. Critical nursing points:

• Administer with food and abundant fluids (improves tolerance, reduces GI upset)
• Patient will develop orange-yellow discoloration of urine and tears (benign but alarming if not forewarned)
• Sulfasalazine impairs folate absorption → supplement with folic acid 1 mg/day throughout therapy
• Contains sulfonamide moiety → caution in sulfa allergy (though many patients with sulfa allergy tolerate it); discontinue immediately if rash, fever, hepatitis, or cytopenias develop
• Monitor CBC and LFTs at baseline and periodically (rare but serious: agranulocytosis, hemolytic anemia, hepatotoxicity)
• Can cause male infertility (reversible upon discontinuation)

Mesalamine (5-ASA): Newer formulations deliver 5-ASA directly to the colon, bypassing the sulfa component and reducing adverse effects. Various preparations target different regions (e.g., Asacol for terminal ileum/colon, Pentasa for small bowel).

• Typical dose: 2.4–4.8 g/day in divided doses
• Better tolerated than sulfasalazine; no folate supplementation needed
• Still monitor CBC and renal function (rare but possible: interstitial nephritis, myocarditis)
• More expensive than sulfasalazine; cost may limit access in resource-limited Philippine settings

Both agents are typically given for 4–6 weeks to assess response; if effective, continued for maintenance.

CORTICOSTEROIDS:
Corticosteroids (prednisone PO, methylprednisolone IV, hydrocortisone IV) rapidly suppress intestinal inflammation and are reserved for acute flares or as bridges to slower-acting agents. Critical principle: steroids are for acute flares ONLY and are NOT maintenance therapy (chronic use causes Cushingoid effects, infections, osteoporosis, hyperglycemia, psychiatric effects).

Typical dosing: Prednisone 40–60 mg/day PO initially, then taper by 5–10 mg every 3–7 days; or IV methylprednisolone 500 mg–1 g daily for severe flares.

Critical nursing safety points—NEVER STOP CORTICOSTEROIDS ABRUPTLY:

• Prolonged steroid use suppresses the hypothalamic-pituitary-adrenal (HPA) axis; abrupt cessation causes adrenal insufficiency (hypotension, shock, death in severe cases)
• Always taper gradually per MD order, even if patient feels better
• Educate patient: never skip doses, never increase without MD approval, carry steroid alert card
• Monitor for steroid-induced hyperglycemia (check fingerstick glucose if diabetic or high-risk); elevated blood pressure; mood changes; insomnia
• Coordinate prophylaxis for PCP (Pneumocystis jirovecii pneumonia) if prolonged high-dose steroids + immunocompromise
• Facilitate baseline bone density scan (DEXA) if prolonged steroid use anticipated; consider calcium, vitamin D, and bisphosphonate supplementation to prevent steroid-induced osteoporosis

IMMUNOMODULATORS:
When patients become steroid-dependent (requiring unacceptably high steroid doses to maintain remission) or have steroid-refractory disease, immunomodulators like azathioprine (AZA), 6-mercaptopurine (6-MP), and methotrexate are introduced as steroid-sparing agents. These work more slowly (weeks to months for full effect) but allow steroid tapering.

Azathioprine / 6-Mercaptopurine:

• Typical dose: AZA 1–2.5 mg/kg/day; 6-MP 1–1.5 mg/kg/day
• Inhibit purine synthesis, reducing T-cell proliferation
• Critical monitoring: CBC and LFTs baseline and every 4–8 weeks (risk of bone marrow suppression → cytopenias, and hepatotoxicity)
• Educate: avoid live vaccines (immunosuppressed); report fever, sore throat, unusual bruising/bleeding, jaundice
• TPMT (thiopurine methyltransferase) testing recommended before starting to identify patients at risk for severe toxicity (slow metabolizers)

Methotrexate:

• Typical dose: 15–25 mg/week (often SC injection)
• Inhibits dihydrofolate reductase; steroid-sparing in both UC and Crohn's
• Teratogenic (Category X)—absolutely contraindicated in pregnancy; counsel women of childbearing potential on contraception
• Monitor CBC, LFTs, renal function every 4–8 weeks
• Supplement with folic acid 1 mg daily (except the day of methotrexate dose) to reduce toxicity
• Educate: avoid live vaccines, NSAIDs (increase toxicity); report signs of infection, unusual bleeding, elevated liver enzymes

BIOLOGIC AGENTS (Anti-TNF & Beyond):
Biologic agents target specific immune mediators driving intestinal inflammation. Anti-TNF agents are the most widely used:

Infliximab (Remicade):

• Monoclonal antibody against tumor necrosis factor-alpha (TNF-α); used for moderate-to-severe IBD and fistulizing Crohn's
• Dose: 5 mg/kg IV infusion at weeks 0, 2, 6, then every 8 weeks

• CRITICAL PRE-TREATMENT SCREENING (mandatory before ANY biologic):

  • Tuberculosis (TB): CXR and tuberculin skin test (TST) or interferon-gamma release assay (IGRA); if latent TB detected, start TB prophylaxis (isoniazid 9 months or alternative) BEFORE biologic initiation
  • Hepatitis B serology (anti-HBc, anti-HBs, HBsAg); if HBsAg+, coordinate with hepatology for antiviral prophylaxis
  • HIV testing
  • CBC, LFTs, renal function baseline
• Infusion reactions: Educate patient to report fever, chills, rigors, chest tightness, dyspnea during or immediately after infusion; keep epinephrine and antihistamines available
• Post-infusion infection risk: Particularly opportunistic infections (PCP, disseminated TB, fungal infections); counsel to report fever, cough, shortness of breath, lymphadenopathy
• Monitor for peripheral neuropathy (new or worsening neurologic symptoms)
• Rare but serious: tuberculosis reactivation, hepatitis B reactivation (can be fatal), opportunistic infections (PCP, histoplasmosis, coccidioidomycosis), demyelinating disease (MS-like), aplastic anemia

Adalimumab (Humira):

• TNF-α antagonist; administered SC self-injection (improves adherence vs. IV infusions)
• Dose: 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks or 40 mg every week (dosing varies by indication)
• Same pre-treatment screening as infliximab (TB, Hepatitis B, HIV, baseline labs)
• Monitoring similar to infliximab; watch for injection-site reactions (erythema, pruritis)

Other Biologic Agents:

• Vedolizumab (Entyvio): Integrin antagonist; selective for gut homing; fewer systemic immunosuppressive effects than anti-TNF; IV infusion
• Ustekinumab (Stelara): IL-12/23 antagonist; emerging role in IBD

NURSING ROLE IN BIOLOGIC MANAGEMENT (Aligned with RA 9173):
Nurses coordinate patient education, pre-treatment screening, infusion/injection administration, adverse effect monitoring, and adherence support:

1. Pre-Treatment Education: Explain disease process, biologic mechanism, expected benefits (not immediate—may take 4–12 weeks), and critical screening requirements
2. TB/Hepatitis B Screening Coordination: Ensure patient undergoes CXR, TST, and serology; if latent TB detected, coordinate TB prophylaxis initiation BEFORE biologic
3. During Infusions (IV agents): Establish IV access, administer pre-medications (antihistamine, acetaminophen per protocol) to reduce infusion reactions, monitor vital signs every 15–30 minutes during infusion, observe for signs of reaction, and keep emergency medications accessible
4. Post-Infusion Care: Observe for delayed reactions (urticaria, fever); educate on when to seek urgent care (difficulty breathing, chest pain, severe reaction)
5. Injection Training (SC agents): Teach proper SC injection technique, site rotation, refrigeration, and when to seek help if injection refused or feared
6. Ongoing Infection Surveillance: Educate on signs of serious infection (TB recurrence: chronic cough, night sweats, weight loss; fungal: respiratory symptoms; PCP: shortness of breath, dry cough); emphasize reporting any new fever, respiratory symptoms, or lymphadenopathy to gastroenterologist immediately
7. Adherence Support: Address injection anxiety, cost barriers (insurance coverage varies in Philippines), and perceived side effects; connect to patient support programs

In the Philippine healthcare context, biologic availability is often limited to tertiary referral centers and private facilities due to cost; many rural and provincial hospitals rely on sulfasalazine, mesalamine, and corticosteroids. Nurses working in these settings must adapt counseling and emphasize the importance of timely referral for patients failing conventional therapy.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by chronic abdominal discomfort and altered bowel habits in the absence of any structural, inflammatory, or biochemical abnormality on standard testing. IBS affects 10–15% of the global population and is among the most common diagnoses in gastroenterology practice, yet it frequently challenges both clinicians and patients due to its subjective nature and lack of objective diagnostic markers. Understanding IBS is essential for NLE because exam questions often test the nurse's ability to distinguish IBS (functional, benign) from organic IBD, diverticulitis, or malignancy—a critical differential diagnosis.

ROME IV DIAGNOSTIC CRITERIA FOR IBS:
Diagnosis is based on clinical criteria rather than laboratory findings. Patients must have recurrent abdominal pain on average ≥1 day/week for ≥3 months (symptom onset ≥6 months prior) and associated with ≥2 of the following:

1. Related to defecation (pain relieved or worsened by bowel movement)
2. Associated with change in stool frequency
3. Associated with change in stool form/appearance

RED FLAG SYMPTOMS (Organic Disease Indicators—NOT IBS):

• Blood in stool (hematochezia) or tarry stools (melena)
• Weight loss (unintentional >5 kg)
• Nocturnal symptoms (waking from sleep due to GI symptoms)
• Fever
• Family history of inflammatory bowel disease, celiac disease, or colorectal cancer
• Age >60 at symptom onset
• New-onset symptoms (rather than long-standing chronic pattern)
• Anemia (iron-deficiency or otherwise)
• Elevated inflammatory markers (CRP, ESR, fecal calprotectin)

Presence of red flags mandates further investigation (colonoscopy, imaging, labs) to exclude organic pathology. IBS is fundamentally a diagnosis of exclusion—we diagnose IBS only after ruling out IBD, celiac disease, parasitic infection, lactose intolerance, and malignancy.

IBS SUBTYPES (Based on Predominant Stool Pattern):

• IBS-D (Diarrhea-Predominant): Loose/watery stools ≥25% of bowel movements; often presents with urgency and frequency
• IBS-C (Constipation-Predominant): Hard/lumpy stools ≥25% of bowel movements; often painful defecation and straining
• IBS-M (Mixed): Alternates between loose and hard stools depending on day
• IBS-U (Unclassified): Insufficient loose/hard stools to meet other subtypes

PATHOPHYSIOLOGY—Functional Dysfunction:
Unlike IBD (inflammatory) or IBS-adjacent conditions, IBS involves:

1. Altered Gut Motility: Abnormal contractile patterns (postprandial hyperreactivity, prolonged high-amplitude contractions), leading to urgency in IBS-D or ineffective propulsion in IBS-C
2. Visceral Hypersensitivity: Heightened perception of normal GI sensations; the patient's nervous system perceives ordinary amounts of gas, stool, or bowel movement as painful
3. Altered Brain-Gut Axis: Bidirectional communication between the enteric nervous system and central nervous system is dysregulated; stress, anxiety, and mood directly impact bowel function
4. Altered Intestinal Barrier Function: Increased permeability ('leaky gut'), although clinical significance is debated
5. Dysbiosis: Altered colonic microbiota composition; unclear causal relationship to IBS
6. Post-Infectious IBS: 5–10% of IBS cases follow acute infectious gastroenteritis (C. difficile, Campylobacter, Shigella)

CLINICAL PRESENTATION & NURSING ASSESSMENT:

• Abdominal Pain: Cramping, diffuse, often periumbilical or left lower quadrant; relieved by defecation (pathognomonic), worsened by eating or stress
• Altered Bowel Habits: Frequency ranges from <3/week (IBS-C) to >3/day (IBS-D); consistency varies
• Bloating and Distension: Gas sensation disproportionate to objective distension (visceral hypersensitivity)
• Mucus in Stool: Common; benign
• Absence of Alarm Symptoms: No fever, no weight loss, no bloody stools, no nocturnal awakening
• Often Comorbid Anxiety/Depression: Assess mood; stress exacerbates symptoms
• Symptom Variability: Symptoms fluctuate based on stress, menses (in women), food intake, and sleep

Nursing assessment must differentiate IBS from organic pathology using the red flag checklist. If all red flags are absent and Rome IV criteria are met, IBS is probable; further investigation (colonoscopy, labs) is reserved for red flag presence or when diagnosis is uncertain.

MANAGEMENT—Symptom-Targeted & Multimodal:
There is no cure for IBS; management is symptom-based and individualized. Principles include:

1. Patient Education & Reassurance (Critical Foundation):

   • Emphasize IBS is common, benign, and not associated with cancer or inflammatory disease
   • Clarify that while symptoms are real and bothersome, there is no structural damage
   • Explain the brain-gut connection: stress worsens symptoms; relaxation improves them
   • Avoid unnecessary investigations once diagnosis is established (reduces anxiety and healthcare costs)
   • Empower patient to identify personal triggers and develop coping strategies

2. Dietary Modifications:

   • Low-FODMAP Diet: FODMAPs are fermentable oligosaccharides, disaccharides, monosaccharides, and polyols poorly absorbed in the small intestine; they draw water into the lumen and are fermented by colonic bacteria, producing gas and bloating. 60–70% of IBS-D patients improve on low-FODMAP diet. Examples of high-FODMAP foods: wheat, onions, garlic, beans, milk products (lactose), apples, pears, honey, sugar-free foods (artificial sweeteners like sorbitol). Refer to dietitian for structured low-FODMAP trial (4–6 weeks, then selective reintroduction).
   • Identify & Avoid Personal Triggers: Encourage food diary; common triggers are spicy foods, caffeine, alcohol, fatty foods, dairy (if lactose-intolerant)
   • Adequate Fiber (IBS-C): Gradual increase in soluble fiber (oats, barley, vegetables) supports stool bulk and regularity; insoluble fiber (wheat bran) may worsen IBS-D
   • Regular Meal Times: Irregular eating exacerbates symptoms; consistent meal timing stabilizes bowel motility
   • Adequate Hydration: 2–3 liters/day supports stool passage

3. Lifestyle Modifications:

   • Stress Management: Cognitive-behavioral therapy (CBT), mindfulness meditation, yoga, deep breathing; stress reduction directly improves symptoms
   • Regular Exercise: 30 minutes moderate activity most days improves GI motility and mood
   • Sleep Hygiene: 7–9 hours/night; poor sleep worsens IBS
   • Limit Caffeine & Alcohol: Both stimulate GI motility and exacerbate IBS-D

4. Pharmacologic Management (Symptom-Targeted):

   • For IBS-D (Diarrhea):

     • Loperamide (Imodium) 2–4 mg TID before meals; slows motility and increases stool water absorption; avoid if fever or bloody stools (risk of toxic megacolon or prolonged infection)
     • Dicyclomine (antispasmodic): Reduces cramping; take 20 mg QID
     • Alosetron (5-HT3 antagonist): Reduces urgency and diarrhea; only in women with severe IBS-D (risk of ischemic colitis limits use)

   • For IBS-C (Constipation):

     • Bulk-forming agents: Psyllium husk 3.5–10 g/day; start low and increase gradually (too much can cause bloating); take with plenty of water
     • Osmotic laxatives: Lactulose 15–30 mL/day, or polyethylene glycol 3350 (MiraLAX) 17 g/day; gentler than stimulant laxatives
     • Lubiprostone (prostaglandin analog): Enhances secretion and motility; 24 mcg BID
     • Linaclotide (guanylate cyclase-C agonist): Increases fluid secretion and accelerates transit; 290 mcg once daily
     • Avoid stimulant laxatives (bisacodyl, senna) long-term due to dependency risk

   • For Bloating/Gas:

     • Simethicone: Reduces surface tension of gas bubbles; 80–160 mg after meals and bedtime
     • Dietary fiber adjustment: May paradoxically worsen bloating initially; increase gradually

   • For Mood/Anxiety (Often Comorbid):

     • Low-dose tricyclic antidepressants (TCA): Amitriptyline 10–50 mg at bedtime; improves pain perception and mood; side effect: constipation (beneficial in IBS-D)
     • SSRIs: Paroxetine, sertraline; improve depression/anxiety; may help bloating; side effect: diarrhea (may worsen IBS-D)
     • Refer to mental health professional: CBT and psychotherapy are highly effective

5. Monitoring & Follow-Up:

   • Reassess diagnosis if red flags emerge (new blood in stool, weight loss, fever)
   • Review medication adherence and side effects
   • Periodically reassess need for continued pharmacotherapy (may achieve symptom control with lifestyle alone)
   • Address comorbid depression/anxiety

NURSING DIAGNOSES & INTERVENTIONS (NANDA-I):

• Chronic Pain related to visceral hypersensitivity and altered motility → Educate on pain-trigger identification; teach relaxation and stress-management techniques; apply heat (warm water bottle) for cramping; support symptom-targeted pharmacotherapy
• Diarrhea (IBS-D) related to altered bowel motility → Educate on high-FODMAP foods and caffeine avoidance; coordinate antidiarrheal medications; ensure access to bathroom; monitor hydration status
• Constipation (IBS-C) related to altered motility and low-residue intake → Educate on high-fiber diet, adequate fluids, and exercise; coordinate laxative therapy; establish regular toileting routine
• Anxiety related to unpredictable bowel symptoms and social impact → Provide reassurance (IBS is benign, not life-threatening); teach stress-reduction techniques (breathing, progressive muscle relaxation, mindfulness); refer to mental health or support groups; normalize social concerns (many people have IBS)

TEACHING POINTS FOR IBS PATIENTS (Applicable in Philippine Context):

• IBS is common and benign; it will not progress to IBD or cancer
• Symptoms wax and wane; stress, certain foods, and hormonal changes (menses) trigger flares
• Identify and avoid your personal triggers (keep a food/symptom diary)
• Regular meals, adequate fiber, and hydration support GI function
• Stress management (yoga, deep breathing, mental health support) directly improves symptoms
• Medications can manage symptoms but are not cures; lifestyle is foundational
• Adequate sleep and exercise reduce symptom severity
• Support groups and counseling help with anxiety and social isolation concerns
• Avoid unnecessary testing once diagnosis is established (reassurance reduces health anxiety)

Diverticular disease encompasses two related conditions: asymptomatic diverticulosis (presence of colonic outpouchings) and symptomatic diverticulitis (inflammation/infection of diverticula). This is a prevalent disorder in developed nations with low-fiber diets and is increasingly recognized in the Philippines due to Westernization of dietary patterns. Understanding diverticular disease is essential for NLE because exam questions test the nurse's ability to recognize acute diverticulitis presenting to the emergency department and differentiate it from other causes of acute abdomen.

DIVERTICULOSIS—FORMATION & RISK FACTORS:
Diverticula are small outpouchings (5–10 mm) of the colonic mucosa and submucosa through the muscular layer, typically occurring at points of vascular penetration where the taeniae coli (longitudinal muscle bands) are weak. The sigmoid colon is most commonly affected (90%) due to its narrower diameter and higher intraluminal pressures per Laplace's law.

Pathophysiology of Formation:

1. Low-Fiber Diet: Results in small-caliber stools requiring increased colonic segmentation (contraction) to propel stool, elevating intraluminal pressure
2. Chronic Constipation & Straining: Repeatedly elevated pressures stress the colonic wall
3. Aging & Loss of Colonic Elasticity: Reduced muscle compliance and increased fibrosis with age
4. Genetic Predisposition: Some individuals are more susceptible to diverticula formation

Epidemiology: Diverticulosis increases with age (present in 50% of people >60 years); prevalence is higher in Western societies with low-fiber intake and lower in African and Asian populations with high-fiber traditional diets.

DIVERTICULOSIS (Uncomplicated):
Most people with diverticulosis are asymptomatic and discovered incidentally on colonoscopy or imaging done for unrelated reasons. Asymptomatic diverticulosis does NOT routinely require treatment; prophylactic antibiotics are no longer recommended for uncomplicated diverticulosis. However, some patients experience chronic or intermittent symptoms of diverticulosis:

• Mild left lower quadrant pain or cramping
• Bloating and distension
• Altered bowel habits (constipation or mild diarrhea)

Management of symptomatic uncomplicated diverticulosis emphasizes prevention of diverticulitis:

• High-Fiber Diet: 25–35 g/day of dietary fiber from fruits, vegetables, whole grains, legumes (once healed, fiber is preventive; during acute flares, low-fiber diet is given)
• Adequate Fluids: 2–3 liters/day
• Regular Exercise: Promotes colonic motility and prevents constipation
• Avoid Straining: Teach proper toileting technique (sit for 10–15 minutes, never strain; use osmotic laxatives if needed)
• Avoid NSAIDs: Some studies suggest NSAIDs increase diverticulitis risk; acetaminophen preferred for analgesia

DIVERTICULITIS (Acute Inflammation/Infection):
When a diverticulum becomes obstructed (typically by fecal material or food residue), the trapped bacteria proliferate, leading to inflammation and infection of the diverticulum and surrounding tissue.

Clinical Presentation (Acute Diverticulitis):

• Localized Abdominal Pain: Most commonly LEFT LOWER QUADRANT (sigmoid location); pain is usually sudden in onset and progressive over hours to days
• Fever: Often 38–39°C (mild-moderate); high fever (>39°C) or shock suggests perforation/peritonitis
• Altered Bowel Habits: Constipation or diarrhea; frequency changes
• Urinary Symptoms: Dysuria, frequency (if inflammation irritates adjacent bladder in women)
• Nausea/Vomiting: Less common than in small-bowel obstruction
• Rebound Tenderness & Guarding: Localized to LLQ; severe peritoneal signs suggest perforation

Clinical Severity Classification (Hinchey Classification—used radiologically):

• Stage I: Uncomplicated diverticulitis (inflammation only)
• Stage II: Localized abscess
• Stage III: Generalized peritonitis (rupture with abdominal cavity contamination)
• Stage IV: Fecal peritonitis (massive contamination)

Diagnostics:

• CT Abdomen/Pelvis with IV Contrast: Gold standard for acute diverticulitis; shows thickened colonic wall, fat stranding, diverticula, and complications (abscess, perforation). CT guides staging and management decisions.
• Laboratory: WBC elevated (10,000–15,000 typically; >15,000 suggests severe disease or complications); CRP and procalcitonin elevated
• Imaging Avoided Acutely: AVOID colonoscopy and barium enema during acute inflammation (rupture risk from insufflation or contrast); perform these 4–6 weeks after recovery to assess for underlying malignancy or exclude other pathology
• Urinalysis: May show WBCs if inflammation extends to bladder; helps exclude urinary pathology

MANAGEMENT OF ACUTE DIVERTICULITIS:

Mild-to-Moderate Uncomplicated Diverticulitis (Hinchey Stage I):

• NPO or Clear Liquids: Bowel rest
• IV Fluids: Balanced electrolyte solution (NSS or D5NSS with KCl) to maintain hydration

• Antibiotics: Gram-negative and anaerobic coverage; typical regimens include:

  • Outpatient oral: Ciprofloxacin 500 mg BID + metronidazole 500 mg TID × 7–10 days (mild cases, reliable follow-up)
  • Inpatient IV: Ceftriaxone 1–2 g daily + metronidazole 500 mg TID, or piperacillin-tazobactam 4.5 g TID (covers gram-negative and anaerobes)
• Analgesia: Acetaminophen preferred; avoid NSAIDs (may increase recurrence risk)
• Reassess in 2–3 Days: If improving, advance diet (low-fiber initially); if worsening despite antibiotics, consider imaging to exclude complications
• Diet Progression: After acute inflammation resolves (typically 3–5 days), gradually introduce low-residue diet, then transition to high-fiber over 1–2 weeks
• Follow-up Colonoscopy: Scheduled 4–6 weeks after recovery to exclude malignancy (especially in new-onset diverticulitis, age >50)

Complicated Diverticulitis (Perforation, Abscess, Peritonitis):

• Abscess (Stage II): If <4 cm, treat medically with antibiotics as above and repeat imaging to confirm resolution. If >4 cm or patient clinically deteriorating, percutaneous drainage (usually by interventional radiology) ± antibiotics may be required

• Perforation/Generalized Peritonitis (Stage III–IV): SURGICAL EMERGENCY

  • STAT CT to confirm perforation
  • NPO, place NGT for decompression
  • Aggressive IV fluids, broad-spectrum antibiotics (cover gram-negative, anaerobes, gram-positive)
  • Urgent surgical consultation; likely requires emergency laparoscopy or open surgery for source control (resection of diseased segment, diverting colostomy, or primary anastomosis depending on Hinchey stage and surgeon preference)

NURSING INTERVENTIONS IN ACUTE DIVERTICULITIS:

Immediate (Emergency/Acute Care Setting):

1. Triage & Pain Assessment: Assess severity on pain scale (0–10); severe pain with fever suggests perforation/peritonitis (urgent surgical consult)
2. Establish IV Access: Two large-bore IVs for potential fluid resuscitation and antibiotic administration
3. NPO & NGT if Indicated: Place NPO; if vomiting or severe ileus, place NGT for decompression and low intermittent suction
4. Fluid & Electrolyte Management: Initiate IV fluid replacement (typically 1.5–2 L/hour of NSS or balanced electrolyte solution); monitor I&O, urine output goal 200–300 mL/hour; repeat serum electrolytes after first liter and every 4–6 hours until stable
5. Antibiotic Administration: Administer first dose of IV antibiotics promptly (time to first antibiotic <1 hour per sepsis protocol)
6. Imaging Coordination: Arrange STAT CT abdomen/pelvis with IV contrast (excludes other diagnoses, confirms diverticulitis, guides staging and treatment)
7. Monitor for Peritonitis: Assess abdomen hourly for peritoneal signs (increasing pain, rigidity, rebound tenderness, absent bowel sounds, fever spike); if present, notify physician immediately (suggests perforation)
8. Infection Surveillance: Monitor vital signs every 15–30 minutes initially; fever management (antipyretic, cool environment); monitor CBC trend (WBC should begin declining on antibiotics within 24–48 hours)

Ongoing (Hospital Course—Mild-Moderate Uncomplicated):

1. Monitor Response to Therapy: Assess pain trend (should decrease by 24–48 hours); reassess fever (should decline); trending WBC (should improve)
2. Diet Advancement: After 2–3 days if improving, advance from NPO to clear liquids, then low-residue diet (white bread, rice, eggs, plain chicken, applesauce), then gradually to high-fiber over subsequent week
3. Patient Education: Once acute phase resolves, educate on high-fiber diet, hydration, exercise, and signs of recurrence (return of LLQ pain, fever)
4. Discharge Planning: Ensure patient understands outpatient antibiotic course (if discharged on oral antibiotics), signs to watch for (fever, increased pain, inability to eat/drink), and follow-up appointment timing (infectious disease if on IV antibiotics; primary care within 1 week; gastroenterology 4–6 weeks for colonoscopy)

Prevention of Recurrence:

• High-Fiber Diet: 25–35 g/day from whole grains, fruits (skin), vegetables, legumes; increase gradually to avoid bloating
• Adequate Fluids: 2–3 L/day
• Regular Exercise: 30 min moderate activity most days
• Avoid NSAIDs: Acetaminophen for analgesia instead
• Elective Colonic Resection: Historically recommended after first attack; currently, elective surgery is individualized based on recurrence risk, patient age, comorbidities, and patient preference. Guidelines suggest considering elective resection after 2 attacks or 1 attack in immunocompromised patients (increased recurrence and severe disease risk)

COMPLICATIONS OF DIVERTICULAR DISEASE:

• Abscess: Localized collection of pus; may require percutaneous drainage
• Perforation & Peritonitis: Life-threatening; requires emergency surgery
• Fistula: Abnormal communication between colon and bladder (colovesical—most common), skin, vagina, or small bowel; present with pneumaturia (air in urine) or fecaluria if colovesical; usually requires surgical resection
• Obstruction: From stricture formation or acute inflammation; may resolve medically or require surgery if persistent
• Uncontrolled Sepsis: If source control inadequate; high mortality if not surgically drained/resected

DIFFERENTIAL DIAGNOSIS (NLE Frequently Tests This):
Left lower quadrant pain with fever could be:

• Diverticulitis (sigmoid diverticula)
• IBD (Crohn's disease of colon; usually chronic history, bloody stool, malabsorption)
• Inguinal Hernia (palpable hernia, history of lifting)
• Nephrolithiasis (flank pain, hematuria, positive CVA tenderness)
• Pyelonephritis (dysuria, frequency, CVA tenderness, urinalysis shows WBCs/nitrites)
• Gynecologic (ectopic pregnancy, pelvic inflammatory disease if female; history of sexual activity, positive β-hCG)

CT imaging definitively differentiates these; history and physical exam guide initial management pending imaging.

Appendicitis is acute inflammation of the vermiform appendix, a small tubular structure attached to the medial aspect of the cecum at the junction of the small and large intestines. Appendicitis represents the most common cause of acute abdomen requiring emergency surgery in both developed and resource-limited settings; it is a frequent NLE exam topic because nurses must rapidly recognize classic presentations, implement critical safety interventions (never apply heat, laxatives, or enemas), and coordinate emergency surgical evaluation. Delays in diagnosis and treatment increase perforation risk, peritonitis, and mortality, making nursing vigilance essential.

EPIDEMIOLOGY & PATHOPHYSIOLOGY:
Appendicitis can occur at any age but peaks in the second and third decades of life (peak incidence 10–19 years). Males and females are equally affected. Pathophysiology involves obstruction of the appendiceal lumen by:

1. Fecalith (most common in Western populations, ~30% of cases)
2. Lymphoid Hyperplasia (viral infection, IgA nephropathy; common in children)
3. Tumor (appendiceal carcinoid, mucinous lesions; rare, ~1% of cases)
4. Foreign Body or Food Residue (uncommon)

Lumen obstruction traps bacteria (normal appendiceal flora: E. coli, Bacteroides, Peptostreptococcus), leading to rapid bacterial proliferation, mucosal ulceration, and invasion of the appendiceal wall. If obstruction persists, ischemia develops, followed by perforation into the peritoneum, releasing enteric bacteria and fecal material into the abdominal cavity and causing peritonitis—a life-threatening emergency.

TIMELINE OF APPENDICITIS:

• Acute Phase (0–12 hours): Initial obstruction; visceral inflammation begins; mucosal layer affected; pain is visceral (dull, diffuse, periumbilical)
• Inflammation Phase (12–24 hours): Transmural inflammation; parietal peritoneum becomes inflamed; pain localizes to RLQ at McBurney's point (transition from visceral to somatic innervation); rebound tenderness appears
• Perforation Phase (>24–48 hours if untreated): Appendiceal wall ruptures; purulent material and bacteria spill into peritoneal cavity; patient may report SUDDEN RELIEF of pain (appendix wall ruptures, releasing tension) followed by WORSENING pain and peritoneal signs (peritonitis); high fever, tachycardia, shock if massive contamination

CLINICAL PRESENTATION (CLASSIC TRIAD):

1. Abdominal Pain:

   • INITIAL (first 6–12 hours): Periumbilical or epigastric, dull, crampy, visceral quality (felt deep inside)
   • CLASSIC MIGRATION: Pain moves from periumbilical region to the RIGHT LOWER QUADRANT, localizing at McBurney's Point (imaginary point 1/3 distance from right anterior superior iliac spine to umbilicus—surface landmark for appendix)
   • Later Stages: Sharp, somatic pain in RLQ; worsens with movement, coughing, laughing
   • Post-Perforation: Sudden relief followed by generalized severe abdominal pain (peritonitis)

2. Associated Symptoms:

   • Fever (typically low-grade 38–38.5°C; higher fever in perforation)
   • Anorexia (often first symptom; patient says "I feel sick")
   • Nausea and Vomiting (occurs AFTER pain onset, distinguishing appendicitis from gastroenteritis where vomiting precedes pain)
   • Constipation or Diarrhea (variable)
   • Urinary symptoms if appendix irritates bladder (dysuria, frequency)

3. Physical Exam Findings (Signs of Peritoneal Irritation):

   • Rebound Tenderness (Blumberg's Sign): Palpate the abdomen, then quickly withdraw hand; if patient winces or guards from withdrawal, peritoneal inflammation is present; highly specific for peritonitis
   • Guarding: Voluntary or involuntary muscle rigidity during palpation of RLQ
   • Rovsing's Sign: Palpate the LEFT lower quadrant; if patient experiences RIGHT lower quadrant pain, suggests appendiceal inflammation (referred pain from RLQ peritoneum)
   • Psoas Sign: Flexion of right hip against resistance causes RLQ pain (psoas muscle adjacent to appendix)
   • Obturator Sign: Internal rotation of right hip causes RLQ pain (obturator muscle adjacent to appendix)
   • Position: Patient may flex right hip and knee for comfort (fetal position)
   • Bowel Sounds: Initially normal, may decrease as peritoneal irritation progresses

RED FLAG: SUDDEN RELIEF OF PAIN = PERFORATION RISK
The most dangerous clinical scenario is when a patient with severe abdominal pain suddenly reports pain improvement. This often indicates appendiceal rupture (acute decompression), and the patient is at imminent risk for peritonitis and septic shock. This patient requires URGENT imaging and surgical consultation.

DIAGNOSTICS:

• Imaging (Essential for Diagnosis):

  • Ultrasound: First-line in pregnancy, children, and resource-limited settings; operator-dependent; shows non-compressible, dilated appendix (>6 mm), appendicolith, free fluid
  • CT Abdomen/Pelvis with IV Contrast: Gold standard; sensitivity and specificity >95%; shows inflamed appendix, appendicolith, surrounding fat stranding, free fluid, abscess, perforation, pericecal mass
  • MRI: Used in pregnancy (avoids radiation); highly sensitive

• Laboratory:

  • WBC: Elevated (10,000–15,000 typically); very high count (>15,000) or low count suggests complications
  • CRP/Procalcitonin: Elevated; rising values suggest transmural inflammation or perforation
  • Urinalysis: Helps exclude urinary pathology (uremia, kidney stone)
• Clinical Scoring (Alvarado Score / RIPASA Score): Combines clinical and laboratory findings; assists in risk stratification but imaging is definitive

DIFFERENTIAL DIAGNOSIS (Critical for Nurses to Recognize):
RLQ pain can be caused by:

• Appendicitis (classic migration, rebound tenderness, fever)
• Mesenteric Lymphadenitis (viral illness precursor; mild symptoms; resolves without surgery)
• Ovarian Pathology (Women): Ovarian torsion (acute pain, nausea, vomiting), ruptured cyst (mild-moderate pain, no fever)
• Ectopic Pregnancy (Women): β-hCG+, vaginal bleeding, hemodynamic instability
• Inflammatory Bowel Disease: Chronic history, diarrhea, weight loss, bloody stools
• Ureterolithiasis: Colicky flank pain, hematuria, CVA tenderness
• Gastroenteritis: Vomiting precedes pain; diffuse cramping; diarrhea; may have fever
• Inguinal Hernia: Palpable hernia; history of straining or lifting

CRITICAL SAFETY INTERVENTIONS (ABSOLUTE CONTRAINDICATIONS—HIGH-YIELD NLE POINT):
The most important nursing interventions in suspected appendicitis are what NOT to do. These interventions are contraindicated because they increase blood flow to the appendix (heat) or increase intestinal motility and pressure (laxatives, enemas), risking rupture and peritonitis:

1. NEVER APPLY HEAT TO THE ABDOMEN (No heating pad, no warm compress, no hot water bottle)

   • Rationale: Heat increases circulation to the inflamed appendix, accelerates inflammatory process, and increases perforation risk
   • Alternative: Use cold compress for comfort if desired (though avoid vigorous application)

2. NEVER ADMINISTER LAXATIVES OR ENEMAS

   • Rationale: Laxatives and enemas increase intestinal peristalsis and pressure, pushing bacteria through the appendiceal wall and causing perforation
   • Constipation is managed with patient reassurance; stool frequency normalizes after appendectomy
   • If MD orders bowel prep inadvertently (before imaging clarifies appendicitis), clarify imaging findings first

3. AVOID STRONG ANALGESICS UNTIL DIAGNOSIS CONFIRMED (Per facility protocol; some facilities allow acetaminophen; avoid NSAIDs if possible)

   • Rationale: Historically, analgesics were withheld to prevent masking of peritoneal signs. Modern evidence suggests judicious analgesia doesn't impair diagnostic accuracy; however, strong opioids may cloud patient's ability to localize pain, potentially delaying diagnosis. Current trend is acetaminophen or mild analgesia acceptable; check facility protocol

NURSING INTERVENTIONS IN SUSPECTED APPENDICITIS:

Immediate (Triage & Emergency Department):

1. Rapid Assessment: History focusing on pain onset, migration (periumbilical → RLQ), associated symptoms (anorexia, nausea, fever)
2. Abdominal Exam: Palpate carefully, assessing McBurney's point, checking for rebound tenderness, guarding, and signs of peritonitis
3. NPO Status: Place patient NPO pending imaging and possible emergency surgery (maintain fasting to allow safe anesthesia induction)
4. IV Access: Establish two large-bore IVs (anticipate fluid replacement and medication administration)
5. Imaging Coordination: Arrange STAT ultrasound or CT (decision based on clinical suspicion, imaging availability, and facility resources)
6. Baseline Labs: Obtain CBC, CMP, β-hCG (if female of reproductive age), urinalysis, cross-match (anticipate OR)
7. Positioning: Semi-Fowler's position or right side flexed for comfort (do NOT apply heat)
8. Patient Education: Explain that appendicitis is a surgical condition; appendectomy is definitive treatment; surgery is usually within hours of confirmation

During Diagnostic Workup:

1. Monitor for Clinical Deterioration: Assess for signs of perforation (sudden pain relief, fever spike, increased rigidity, shock—hypotension, tachycardia, cold skin). If perforation suspected, notify MD immediately and prepare for emergency OR
2. IV Hydration: If delay before surgery anticipated, initiate IV fluid replacement (typically NSS or D5NSS)
3. Serial Exams: If clinical diagnosis unclear, exam may be repeated q1–2 hours; communicate any changes to MD
4. Anxiety Management: Appendicitis is frightening; provide reassurance that appendectomy is safe, common, and definitive

Pre-Operative (Confirmed Appendicitis):

1. NPO Confirmation: Ensure patient has not eaten/drunk after midnight (or per anesthesia protocol)
2. Pre-Op Checklist: ID band, chart review, medications list (hold certain meds per protocol), vital signs, lab results available
3. Informed Consent: Confirm consent is signed; answer questions; explain post-op expectations (pain, recovery timeline, activity restrictions)
4. GI Prep: No enemas; simple NPO sufficient
5. IV Antibiotics: Typically initiated before incision per surgical site infection prevention protocol (e.g., cefazolin 2 g IV)
6. Transport to OR: Ensure patient on stretcher with side rails up; communicate any special concerns to perioperative team

Post-Operative (After Appendectomy):

Immediate Post-Op (PACU—Recovery Room):

1. Vital Signs & Consciousness: Monitor q5–15 minutes until stable; assess level of consciousness and orientation
2. Pain Assessment: Assess pain location, severity; provide analgesia as ordered (usually IV morphine or ketorolac initially)
3. Surgical Site Assessment: Check dressing for excessive bleeding; assess incision site (simple laceration for laparoscopic appendectomy, larger for open)
4. Nausea Management: Antiemetics as ordered (post-op nausea is common); ice chips only initially
5. IV Fluids: Continue running; assess urine output (Foley catheter in place if general anesthesia prolonged)
6. Complications Assessment: Watch for signs of bleeding (excessive drainage, hemodynamic instability), infection (fever, foul-smelling drainage), or anastomotic leak if other bowel injury repaired

Hospital Recovery (Post-Op Days 1–3 or Until Discharge):

1. Pain Management: Transition to oral analgesia as tolerated; pain should progressively decrease; increasing or severe pain suggests complication
2. Ambulation: Encourage early mobilization (within 6–24 hours) to prevent thrombosis and promote recovery
3. Diet Progression: NPO initially, then sips, then clear liquids, then regular diet as tolerated (bowel function returns; most patients eat within 24 hours)
4. Wound Care: Keep dressing clean/dry; remove dressing per protocol (often day 1–2); assess for redness, swelling, drainage, dehiscence
5. Antibiotic Course: Typically 1 pre-op dose + possible 24 hours post-op; uncomplicated appendicitis does not require prolonged antibiotics

6. Monitor for Complications:

   • Infection/Sepsis: Fever >38.5°C, tachycardia, increased pain, foul wound drainage → notify MD; may require imaging and broader antibiotics
   • Anastomotic Leak (if bowel repair performed): Fever, abdominal pain, peritonitis signs → emergent imaging; possible return to OR
   • Thrombosis (DVT/PE): Leg swelling/pain, shortness of breath → assess for signs; recommend DVT prophylaxis (early ambulation, sequential compression devices in high-risk)
   • Adhesions (future complication): Educate that scar tissue may cause occasional pain; minimize future abdominal surgeries when possible

Discharge Planning & Patient Education:

• Activity: Light duty × 1–2 weeks; return to normal activity by 3–4 weeks; avoid heavy lifting, vigorous exercise
• Wound Care: Keep dry; remove bandage if present; watch for signs of infection (increasing redness, warmth, swelling, pus)
• Diet: Return to normal; no restrictions
• Pain Management: Take acetaminophen or ibuprofen as needed for residual discomfort; contact if severe pain develops
• Work/School: Typically return within 1–2 weeks for sedentary work; 3–4 weeks for physical labor
• When to Seek Emergency Care: Fever >38.5°C, increasing abdominal pain, wound drainage/gaping, chest pain/shortness of breath, leg swelling, persistent vomiting
• Follow-Up: Post-op visit with surgeon in 1–2 weeks to assess healing

COMPLICATIONS OF APPENDICITIS:

• Perforation: Occurs in 20–30% of cases if diagnosis delayed >48 hours; leads to peritonitis and potential sepsis/death
• Peritonitis: Generalized abdominal inflammation from perforated appendix; can lead to septic shock
• Appendiceal Abscess: Localized collection of purulent material; may form if perforation is walled off; treated with drainage (percutaneous or surgical) and antibiotics
• Wound Infection: Post-operative; increased risk if perforation pre-operatively
• Adhesions: Scar tissue post-operatively; may cause intermittent abdominal pain or future obstruction
• Mortality: <1% with prompt diagnosis and treatment; increases significantly with delayed diagnosis and peritonitis

Intestinal obstruction is interruption of normal passage of intestinal contents through the GI tract, classified as mechanical (physical blockage) or functional (paralytic ileus—absence of normal motility without physical obstruction). Obstruction is a medical and surgical emergency; delays in diagnosis and treatment lead to complications (strangulation, perforation, sepsis, death). Nurses must rapidly recognize obstruction, implement decompression and supportive measures, and coordinate emergency evaluation. NLE testing emphasizes level-specific manifestations (small bowel vs. large bowel) and electrolyte disturbances associated with high vomiting (metabolic alkalosis in SBO).

TYPES OF MECHANICAL OBSTRUCTION:

1. Adhesions (Most common in developed countries; ~60% of SBO cases)

   • Scar tissue forming between loops of bowel after prior abdominal surgery, peritonitis, or trauma
   • Can occur years after initial surgery
   • In the Philippines, limited surgical intervention in rural areas means adhesions may be less common than in developed nations

2. Hernia (Inguinal, femoral, umbilical, ventral)

   • Protrusion of bowel through fascial weakness
   • Risk factors: heavy lifting, straining, obesity, pregnancy, family history

3. Tumor (Colon cancer most common)

   • Often left-sided (descending/sigmoid); presents as large-bowel obstruction
   • Adenocarcinoma is most common type

4. Volvulus (Twisting of bowel on its mesentery)

   • Sigmoid volvulus more common in elderly, patients with chronic constipation
   • Cecal volvulus less common
   • Can present acutely with severe pain or gradually with intermittent symptoms

5. Intussusception (Telescoping of one bowel segment into an adjacent segment)

   • Most common in children (ileocolic intussusception)
   • Can occur in adults (often from a lead point like tumor or Meckel's diverticulum)
   • Presents acutely with colicky pain and bloody stools

6. Stricture (Narrowing from fibrosis, inflammation, or prior surgery)

   • From Crohn's disease, ischemia, radiation, or surgical complications
7. Foreign Body (Rare in developed countries; more common in resource-limited settings with limited healthcare education)

PATHOPHYSIOLOGY OF MECHANICAL OBSTRUCTION:

1. Proximal to obstruction: Bowel distends with swallowed air and intestinal secretions (bile, gastric juice, pancreatic secretions, small intestinal secretions) because normal distal propulsion is blocked
2. Mucosal pressure necrosis: Increased intraluminal pressure from distension leads to mucosal ulceration and bacterial translocation
3. Fluid sequestration: Large volume of fluid (3–4 L/day normally secreted into GI tract) pools in obstructed bowel, not reabsorbed → dehydration, hypovolemia, and electrolyte loss
4. Bacterial overgrowth & translocation: Stagnant intestinal contents allow bacterial proliferation; bacteria breach damaged mucosa → portal blood bacteremia and potential sepsis
5. Strangulation (Vascular Compromise): If obstruction compromises mesenteric blood supply (e.g., volvulus, tight hernia), bowel becomes ischemic → transmural infarction, perforation, and peritonitis (surgical emergency)

LEVEL-SPECIFIC PRESENTATIONS: SMALL-BOWEL OBSTRUCTION (SBO) vs. LARGE-BOWEL OBSTRUCTION (LBO)

CLINICAL PRESENTATION OF OBSTRUCTION:

Early Phase (First 6–12 hours):

• Sudden onset colicky pain (cramping, intermittent, waves of severity correlating with peristaltic rushes trying to push past obstruction)
• Mild abdominal distension
• Hyperactive bowel sounds (increased frequency, high-pitched, "rushing")
• Nausea, then vomiting (early in SBO, late in LBO)
• Minimal systemic signs (normal vital signs, alert)

Progressive Phase (12–24 hours):

• Continuous abdominal pain (cramping quality may become more constant)
• Progressive distension (especially in LBO)
• Bilious or feculent vomiting (feculent = late-phase obstruction indicator; indicates bacterial overgrowth in stagnant bowel)
• Dry mucous membranes, poor skin turgor (dehydration from fluid sequestration and vomiting)
• Decreased urine output (oliguria from hypovolemia)
• Electrolyte imbalances: Hypokalemia (weakness, cardiac dysrhythmias), hyponatremia (confusion, cerebral edema risk), metabolic alkalosis in SBO (from gastric acid loss via vomiting)

Late Phase/Strangulation (24–48+ hours if untreated):

• Severe unrelenting pain (visceral pain becomes somatic, indicating peritoneal involvement; no longer colicky)
• Rigid abdomen with rebound tenderness (peritonitis from bacterial translocation through damaged mucosa or perforation)
• Fever (reflects systemic inflammation/sepsis)
• Tachycardia, hypotension, shock (septic shock from bacterial translocation and perforation)
• Bowel sounds absent (paralytic ileus superimposed; bowel is now essentially non-functional)
• Elevated WBC, left shift (infection/inflammation)
• Lactic acidosis (tissue hypoxia from compromised perfusion)

DIAGNOSTICS:

Imaging:

• Abdominal X-ray (Upright & Supine): First-line; assesses for distension, air-fluid levels, transition points; upright view shows air-fluid levels (SBO shows "string-of-pearls," stacked levels; LBO shows dilated colon with transition point)
• CT Abdomen/Pelvis with IV Contrast: Gold standard; shows transition point, bowel wall enhancement (perfusion), free fluid/blood, strangulated vs. non-strangulated obstruction
• Ultrasound: Can visualize dilated bowel loops, peristalsis; useful in pregnancy; operator-dependent

Laboratory:

• CBC: WBC elevated if infected; Hgb/Hct may be falsely elevated (hemoconcentration from dehydration)

• CMP: Assess electrolytes (K, Na, Cl), acid-base status

  • SBO: Metabolic alkalosis (pH >7.45, HCO3- elevated from gastric acid loss); hypokalemia (K <3.5); hyponatremia (Na <130)
  • LBO: Variable electrolyte derangement; may progress to metabolic acidosis if prolonged
• Lactate: Elevated if tissue hypoxia/strangulation present (ominous sign)
• ABG: Assess acid-base status and oxygen saturation

CONSERVATIVE VS. OPERATIVE MANAGEMENT:

Non-Operative (Conservative) Management—For Partial SBO WITHOUT Strangulation:

• Selected partial small-bowel obstructions from adhesions can resolve with:

  • NPO: Bowel rest
  • NGT Decompression: Nasogastric tube placement with low intermittent suction to evacuate proximal contents and decompress bowel; provides symptomatic relief (reduces pain and vomiting)
  • IV Fluids & Electrolyte Replacement: Aggressive fluid resuscitation (LR or NSS with electrolyte additives) to restore intravascular volume and urine output; goal urine output 0.5–1 mL/kg/hour; replace ongoing NGT losses with 1:1 ratio (e.g., if NGT output 500 mL/2 hours, replace with 250 mL/hour IV in addition to maintenance fluids)
  • Serial Exams & Imaging: Assess for clinical improvement; repeat CT at 24–48 hours to determine if obstruction resolved or if surgical intervention needed
  • Duration: Typically 48–72 hours of conservative management attempted; if no improvement or deterioration, surgery is indicated
  • Success Rate: 60–70% of partial adhesive SBOs resolve with conservative management

Operative (Surgical) Management—For Complete Obstruction or Strangulation:

• Indications:

  • Complete obstruction (absolute obstipation, no flatus)
  • Signs of strangulation (severe pain, fever, rigidity, peritoneal signs, elevated lactate)
  • Obstruction from hernia, tumor, or volvulus (structural causes requiring surgery)
  • Failed conservative management after 48–72 hours
  • Acute LBO (except partial obstruction in selected cases)
• Procedure: Exploratory laparotomy or laparoscopy; identify obstruction site; treat underlying cause (adhesiolysis, hernia repair, tumor resection, decompression of volvulus, bowel resection if necrotic)

FUNCTIONAL OBSTRUCTION / PARALYTIC ILEUS:
Paralytic ileus (non-mechanical obstruction) results from absence of normal peristalsis despite patent bowel, caused by:

• Post-operative (most common): Normal after abdominal surgery; resolves within 24–72 hours
• Peritonitis: Visceral inflammation inhibits motility
• Electrolyte abnormalities: Hypokalemia (K <2.5 severely impairs peristalsis), hypomagnesemia, hypocalcemia
• Medications: Opioids (decrease motility), anticholinergics
• Severe illness: Sepsis, myocardial infarction, trauma

Management of Paralytic Ileus:

• Treat underlying cause: Correct electrolytes (especially K), discontinue offending medications if possible, treat sepsis/primary illness
• NPO & NGT Decompression: Rest bowel; nasogastric tube if vomiting
• IV Fluids: Maintain hydration and electrolyte balance
• Mobilization: Early ambulation stimulates motility
• Prokinetic Agents: Metoclopramide (blocks dopamine, enhances acetylcholine effect; 10 mg IV/IM/PO TID), domperidone (similar), or neostigmine (acetylcholinesterase inhibitor; use cautiously—can increase parasympathetic effects)
• Avoid opioids: If possible (suppress motility further)
• Time: Most post-operative ileus resolves spontaneously within 72 hours

NURSING INTERVENTIONS IN OBSTRUCTION:

Immediate Assessment & Stabilization:

1. Rapid History: Onset of pain, recent surgery, prior obstructions, constipation status, medications (opioids), signs of strangulation (severe pain, fever)
2. Abdominal Exam: Localize pain, assess guarding/rigidity (peritoneal signs = red flag), auscultate bowel sounds (hyperactive in partial, absent in complete), assess distension
3. NPO Status: Place immediately
4. IV Access: Two large-bore IVs
5. Baseline Labs: CBC, CMP (electrolytes, acid-base status), lactate, blood cultures if fever
6. Imaging: STAT abdominal X-ray (upright & supine); CT if findings unclear or strangulation suspected

7. NG Tube Placement (If Indicated):

   • Technique: Patient sits upright or semi-Fowler's; lubricate tube with water-soluble lubricant; pass through nose into pharynx, have patient swallow to facilitate passage into esophagus and stomach; advance to predetermined length (typically 55–65 cm for adults); confirm placement with X-ray or air insufflation test (listen over epigastrium for "whoosh" sound) or CO2 detector
   • Suction: Low intermittent suction (avoid high suction, which can damage mucosa); some tubes have multiple ports to prevent suction of mucosa
   • Measurement & Documentation: Note tube length at nostril; measure and document output (color, character, volume)

Fluid & Electrolyte Management:

1. Aggressive IV Rehydration: Bolus LR or NSS 1–2 L over first 1–2 hours; then maintenance plus replacement of ongoing losses (NGT output, vomiting)

2. Electrolyte Replacement:

   • SBO (metabolic alkalosis): Typically requires aggressive K and Cl replacement; use LR (contains K 4 mEq/L) or NSS with KCl 20–40 mEq/L added; goal K >3.5 mEq/L (cardiac stability)
   • Monitor: Repeat CMP every 4–6 hours during acute phase; assess QT interval on ECG if severe hypokalemia (risk of arrhythmias)
3. Urine Output Monitoring: Goal 0.5–1 mL/kg/hour; indicates adequate perfusion and renal function

Monitoring for Complications:

1. Strangulation (Surgical Emergency Indicator):

   • Severe, unrelenting pain (not colicky)
   • Fever (T >38.5°C)
   • Rigid abdomen, rebound tenderness (peritonitis)
   • Tachycardia, hypotension (shock)
   • Elevated lactate (tissue hypoxia)
   • Action: Immediately notify surgeon; patient requires urgent laparotomy

2. Perforation:

   • Sudden worsening of pain
   • Board-like rigid abdomen
   • Diffuse peritoneal signs
   • Action: STAT imaging; urgent surgery

3. Sepsis:

   • Fever, tachycardia, tachypnea, altered mental status
   • Elevated WBC, lactate
   • Action: Blood cultures, broad-spectrum antibiotics, fluid resuscitation, ICU monitoring if hemodynamically unstable

NG Tube Maintenance:

1. Patency: Flush tube every 4–6 hours with 30–60 mL normal saline (or per protocol) to maintain patency; if clogged, attempt gentle flushing; if unsuccessful, notify MD (may require repositioning or replacement)
2. Suction Settings: Low intermittent suction (~60–80 cm H2O pressure) to avoid mucosal damage
3. Measurement: Measure and document output every 2–4 hours; assess for color changes (clear → bilious green → feculent)
4. Skin Care: Secure tube at nostril with tape; assess for pressure ulcers on nostril/face; alternate nares if tube in place >3 days to prevent necrosis
5. Oral Hygiene: Mouth rinses and meticulous care (NPO patients may develop dry mouth and dental plaque)

Diet Advancement (If Conservative Management Chosen):

• Assess for resolution: bowel sounds return, pain decreases, flatus passes, patient tolerates sips
• Progression: NPO → sips of water → clear liquids → regular diet (advance slowly; rapid advancement can trigger symptom recurrence)
• Timing: Usually 48–72 hours if improving with conservative care

Patient Education & Discharge (If Discharged Without Surgery):

• Recognize early obstruction signs: cramping pain, vomiting, abdominal distension, absence of flatus
• Adhere to high-fiber diet, adequate fluids, regular exercise (prevent recurrence)
• Avoid heavy lifting, straining
• If history of adhesions, inform all healthcare providers (may affect surgical decision-making in future)
• Report return of symptoms immediately

Post-Operative Management (If Surgery Performed):

• Similar to appendectomy: pain management, early ambulation, diet advancement, wound care
• Special consideration: If bowel resected, watch for short-bowel syndrome manifestations (chronic diarrhea, malabsorption) if extensive resection
• NG tube: May remain in place longer post-operatively if extensive manipulation or anastomosis performed; removed once bowel function returns